EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
The interim results of the Phase III clinical trial of EirGenix breast cancer biosimilar, EG12014 (a proposed trastuzumab biosimilar) have been published at the 2021 San Antonio Breast Cancer Symposium (SABCS21). The primary efficacy endpoint, pCR at the time of surgery, demonstrated equivalence of EG12014 and Herceptin. EG12014 has also demonstrated a comparable safety profile. Abstract number: P2-13-17.
2021-12-08
Associated News
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
2021/03/02
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
Vstrip® COVID-19 Antigen Rapid Test Validated and Approved in India!
2020/09/26
EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
2020/02/03
EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
2019/05/29
EIRGENIX RECEIVED "ASIA'S BEST CMO"
2018/01/31
EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
2013/12/06
EirGenix Inc. Achieves Major Milestone: Breast Cancer Biosimilar Candidate -EG1206A Receives Favorable Response Regarding Phase III Clinical Trial Waiver
On September 24, EirGenix (6589) announced that it has received positive feedback from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during scientific consultations regarding the waiver of Phase III clinical trials for its breast cancer biosimilar candidate, EG1206A (Pertuzumab biosimilar). Consequently, the company has officially terminated the on-going Phase III clinical trial for EG1206A. This decision accelerates the global marketing authorization applications (BLA/MAA) for the product and reduces the originally planned product development expenses. Receiving positive feedback from regulatory agencies reflects EirGenix’s long-standing expertise in biosimilar development and marks a significant milestone in the company’s expansion in the biosimilar market.
2025/10/22